China Inhaled Corticosteroids Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the China Inhaled Corticosteroids Market was valued at USD 1.58 billion in 2025 and is projected to reach USD 2.36 billion by 2032, growing at a CAGR of approximately 5.9% during 2026–2032.
China Inhaled Corticosteroids Market Highlights
| Report Metric | Details |
| Report Name | China Inhaled Corticosteroids Market |
| Market Size 2025 | USD 1.58 billion |
| Market Size 2032 | USD 2.36 billion |
| Absolute Growth 2025–2032 | USD 0.78 billion |
| CAGR 2026–2032 | 5.9% |
| Peak Annual Growth | 7.7% in 2028 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Drug Name/Form, 2025 | Fluticasone (42% share) |
| Leading Indication, 2025 | Asthma / COPD (36% share) |
| Leading Dosage Delivery, 2025 | MDI (37% share) |
| Leading Distribution Channel, 2025 | Prescription Outlets (46% share) |
| Fastest-Growing Drug Name/Form | Budesonide (7.8% CAGR) |
| Fastest-Growing Indication | Long-Term Inflammation (8.7% CAGR) |
| Fastest-Growing Dosage Delivery | DPI (7.8% CAGR) |
| Fastest-Growing Distribution Channel | Drugstores (8.7% CAGR) |
| Growing Sector | respiratory health |
| Key End Users | hospitals, drugstores, ENT clinics, prescription outlets |
China Inhaled Corticosteroids Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Each row of the following table gives one year's estimated growth and the event or demand shift that explains it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 3.5 | The market experienced steady growth due to a significant number of asthma diagnoses. |
| 2023 | 5.9 | Increased awareness campaigns contributed to a faster growth rate in inhaled corticosteroids. |
| 2024 | 6.5 | The rise in COPD prevalence drove demand for inhaled corticosteroids in hospitals. |
| 2025 | 5.0 | A slowdown occurred as the market adjusted to recent healthcare initiatives. |
| 2026 | 6.8 | The introduction of new inhalation devices boosted growth in the inhaled corticosteroids segment. |
| 2027 | 4.1 | The market faced a slowdown as competition intensified among suppliers. |
| 2028 | 7.7 | A surge in asthma cases led to peak growth in inhaled corticosteroid prescriptions. |
| 2029 | 5.2 | The market slowed down slightly due to market saturation in urban areas. |
| 2030 | 7.5 | Increased funding for respiratory health initiatives spurred demand for inhaled corticosteroids. |
| 2031 | 5.3 | The market continued to grow, albeit at a slower pace, due to ongoing healthcare reforms. |
| 2032 | 4.8 | Growth slowed as the market stabilised following years of rapid expansion. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
China Inhaled Corticosteroids Market Synopsis
Inhaled Corticosteroids in China are anti-inflammatory medications primarily used for treating respiratory conditions such as asthma and COPD. These medications are aerosolized and delivered via inhalers or nebulizers. The China Inhaled Corticosteroids Market is expanding due to rising asthma diagnoses and ongoing healthcare investments. Approximately 30 million individuals were diagnosed with asthma in 2022, driving demand for effective treatments. The government's "Healthy China 2030" initiative aims to improve respiratory health, further propelling market growth.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Rising asthma prevalence drives demand for inhaled corticosteroids. | Driver | High | Asthma / COPD |
| Increased healthcare investments enhance treatment accessibility. | Driver | High | Prescription Outlets |
| Growing patient population presents opportunities for new treatment options. | Opportunity | High | ENT Clinics |
| Expansion of drugstores facilitates easier access to medications. | Opportunity | High | Drugstores |
| Regulatory changes can affect the approval process for new drugs. | Restraint | Medium | MDI |
| Market saturation in urban areas limits growth potential. | Restraint | Medium | Hospital Pharmacies |
| Supply chain disruptions can delay product availability for buyers. | Challenge | High | Nebulizer / Inhaler |
| Increasing competition may pressure pricing strategies for suppliers. | Challenge | Medium | Fluticasone |
Evaluation of Drivers in China Inhaled Corticosteroids Market (2026–2032)
Key forces behind demand, with the segment each one moves most, are listed below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increased asthma diagnoses lead to higher demand for inhaled corticosteroids. | Asthma / COPD | In 2023, the National Health Commission reported a 15% increase in asthma prevalence. |
| Growing healthcare investments improve access to respiratory treatments. | Prescription Outlets | The "Healthy China 2030" initiative aims to improve respiratory health services. |
| Rising pollution levels contribute to chronic respiratory diseases. | Fluticasone | The market for inhaled corticosteroids is expected to grow due to increasing pollution levels. |
| New inhalation devices improve treatment options for patients. | MDI | In 2021, the State Drug Administration approved new inhalation devices for asthma treatment. |
| Awareness campaigns drive patient engagement in asthma management. | ENT Clinics | The National Health Commission promotes awareness campaigns for asthma management. |
The Inhaled Corticosteroids market in China is expanding as rising asthma diagnoses, increased healthcare investments, and growing pollution levels drive demand. Approximately 30 million people were diagnosed with asthma in 2022, leading to a surge in prescriptions. In 2023, the National Health Commission reported a 15% increase in asthma prevalence, highlighting the urgent need for effective therapies. New inhalation devices approved in 2021 provide patients with more treatment options, encouraging greater purchasing from healthcare providers.
Evaluation of Restraints in China Inhaled Corticosteroids Market
The main factors holding the market back are set out below.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Regulatory changes can delay the approval of new inhaled corticosteroids. | MDI | In 2023, updated guidelines for inhaled corticosteroid usage were issued by the State Drug Administration. |
| Market saturation in urban areas limits growth potential for suppliers. | Hospital Pharmacies | Urban areas have seen a high concentration of healthcare facilities, creating intense competition. |
| Supply chain disruptions can affect product availability for buyers. | Nebulizer / Inhaler | Recent global supply chain issues have impacted the timely delivery of inhaled medications. |
| Pricing pressures may arise from increased competition among suppliers. | Fluticasone | The growing number of manufacturers in the market intensifies pricing competition. |
| Healthcare budget constraints can limit funding for respiratory health initiatives. | Asthma / COPD | Budget limitations may affect the implementation of respiratory health programs. |
China Inhaled Corticosteroids Market Challenges
Buyers and suppliers in the China inhaled corticosteroids market encounter high production costs, as raw material prices have surged by 20%, increasing expenses for manufacturers and ultimately raising prices for patients. Regulatory hurdles pose another challenge, with compliance to the Chinese Pharmacopoeia delaying product approvals by up to six months, which restricts clinics' access to new inhalation devices. A shortage of skilled respiratory care professionals limits treatment effectiveness, complicating care for the estimated 100 million patients with chronic respiratory diseases. Intense competition among suppliers results in price wars, eroding profit margins for producers and potentially impacting product quality.
Trends in the China Inhaled Corticosteroids Market
Below mentioned are some of the trends shaping the China Inhaled Corticosteroids Market growth.
- Shift from Hospital Pharmacies to Drugstores: Patients are increasingly accessing inhaled corticosteroids through drugstores rather than hospital pharmacies. By 2026, drugstores are projected to grow at a CAGR of 8.7%, reflecting changing consumer preferences for convenience.
- Transition from MDIs to DPIs: Patients are moving towards dry powder inhalers (DPIs) as they seek easier-to-use options. By 2026, DPIs are expected to grow at a CAGR of 7.8%, indicating a shift in delivery preferences.
- Increased Focus on Asthma Management: Healthcare providers are prioritising asthma management through targeted initiatives. The "Asthma Management Program" launched in 2021 aims to improve treatment accessibility for 20 million patients by 2025.
- Growing Adoption of New Inhalation Devices: The approval of new inhalation devices in 2021 has led to increased adoption among patients. This trend is expected to improve treatment options and patient compliance.
Investment Opportunities in the China Inhaled Corticosteroids Market
Below are the investment opportunities with the strongest case in the China Inhaled Corticosteroids Market.
- Supply of New Inhalation Devices: With the approval of new inhalation devices in 2021, there is an opportunity to supply effective products. The demand for effective asthma treatments continues to rise, indicating a market gap.
- Partnerships with Drugstores: The increasing role of drugstores in distributing inhaled corticosteroids presents an opportunity for partnerships. Collaborating with local drugstores can improve market reach and accessibility for patients.
- Investment in ENT Clinics: The growth of ENT clinics in urban areas highlights an opportunity for investment. With over 1,000 clinics providing specialized respiratory care, suppliers can focus on establishing partnerships to meet demand.
- Expansion of Prescription Outlets: The prescription outlet segment is expected to grow, with a share of 46% by 2025. Suppliers should consider entering this segment through partnerships or joint ventures.
Government Initiatives in the China Inhaled Corticosteroids Market
The implementation of various measures supports the inhaled corticosteroids market. The "National Essential Medicines List" approved in 2020 ensures the availability of inhaled corticosteroids in public healthcare. In 2021, the National Health Commission launched the "Asthma Management Program" to improve treatment accessibility for 20 million patients by 2025. Additionally, the Ministry of Health initiated the "Respiratory Health Initiative" in 2022, aiming to reduce respiratory disease mortality by 10% by 2025. These measures enhance the framework for producers and buyers in the market.
Healthcare professionals benefit from training programs established by the Ministry of Education in 2022. This initiative focuses on improving knowledge and skills in respiratory disease management. The National Health Commission also allocates funds for respiratory disease research, with a reported budget of 50 million RMB in 2023. These efforts ensure that healthcare providers are well-equipped to deliver effective treatments, ultimately benefiting patients who rely on inhaled corticosteroids.
Future Insight of the China Inhaled Corticosteroids Market
The China inhaled corticosteroids market is set to evolve by 2032, driven by the "Healthy China 2030" initiative focused on improving respiratory health. Innovations in inhalation devices will enhance patient adherence, exemplified by the recent approval of advanced asthma treatment devices. Increased funding for respiratory disease research will lead to improved therapeutic options, while the prevalence of asthma is expected to reach around 35 million by 2025, boosting demand for inhaled corticosteroids. Awareness campaigns will educate patients, fostering better management of their respiratory conditions.
Market Segmentation Analysis
Each segment group is reviewed below, with the leader by share and the fastest grower by CAGR.
By Drug Name/Form – Fluticasone Dominated, Budesonide Expected to Grow Fastest
According to Shubham Deep, Research Manager at 6Wresearch, the largest drug name/form category in 2025 was Fluticasone, with a 42% share of total revenue. Fluticasone dominates the inhaled corticosteroids market due to its frequent prescription for COPD treatment in hospitals. This widespread use among healthcare professionals ensures its leading position in respiratory care. Over 2026–2032, Budesonide is expected to post the fastest growth, at a CAGR of 7.8%. Budesonide is experiencing rapid growth, primarily driven by its effectiveness in managing asthma, particularly in light of the recent 15% rise in asthma prevalence. This increasing demand positions Budesonide to further solidify its market presence. Suppliers should ensure a steady supply of Budesonide to meet the growing needs of asthma patients effectively.
By Indication – Asthma / COPD Dominated, Long-Term Inflammation Expected to Grow Fastest
With a 36% revenue share in 2025, Asthma / COPD was the largest indication category. Asthma / COPD is the leading indication for inhaled corticosteroids, accounting for a substantial share of prescriptions as it addresses the primary respiratory conditions affecting millions. The high prevalence of asthma in China, with approximately 30 million diagnosed cases, underscores its importance. The quickest growth will come from Long-Term Inflammation, forecast to expand at a CAGR of 8.7% between 2026 and 2032. Long-Term Inflammation is the fastest-growing indication due to the increasing recognition of the need for controlling persistent inflammation in the lungs. This focus aligns with the government's initiatives to improve respiratory health, driving demand for effective treatments. Buyers should consider long-term inflammation management solutions to align with evolving healthcare priorities.
By Dosage Delivery – MDI Dominated, DPI Expected to Grow Fastest
In 2025, MDI led the dosage delivery split with a 37% share. MDI captures the largest market share as it is the most widely used inhaler for delivering precise doses of inhaled corticosteroids. Its established presence in both hospitals and home care settings reinforces its leading role in respiratory treatment. DPI is projected to grow fastest, at a CAGR of 7.8% during 2026–2032. DPI is quickly gaining popularity due to its user-friendly design, making it an attractive option for patients managing chronic respiratory conditions. As more patients opt for DPIs, this segment is poised for significant growth. Suppliers must invest in the development of DPI devices to cater to the increasing demand for user-friendly inhalation solutions.
By Distribution Channel – Prescription Outlets Dominated, Drugstores Expected to Grow Fastest
Prescription Outlets accounted for a 46% market share by distribution channel in 2025. Prescription Outlets hold the largest market share as the primary distribution channel for inhaled corticosteroids, facilitating access through healthcare providers. This established channel ensures that patients receive their medications promptly and reliably. Drugstores are set to record the highest CAGR in this split, 8.7% over 2026–2032. Drugstores are becoming the fastest-growing distribution channel, driven by their convenience and accessibility for patients seeking inhaled corticosteroids. The shift towards self-management of respiratory conditions is accelerating this trend. Suppliers should enhance partnerships with drugstores to improve patient access and address the rising demand for inhaled corticosteroids.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- China Inhaled Corticosteroids Market Outlook
- Market Size of China Inhaled Corticosteroids Market, 2025
- Forecast of China Inhaled Corticosteroids Market, 2032
- Historical Data and Forecast of China Inhaled Corticosteroids Revenues & Volume for the Period 2022 - 2032F
- China Inhaled Corticosteroids Market Trend Evolution
- China Inhaled Corticosteroids Market Drivers and Challenges
- China Inhaled Corticosteroids Price Trends
- China Inhaled Corticosteroids Porter's Five Forces
- China Inhaled Corticosteroids Industry Life Cycle
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Drug Name/Form for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Budesonide for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Fluticasone for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Beclomethasone for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Mometasone for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Indication for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Asthma / COPD for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Long-Term Inflammation for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Allergies / Wheezing for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Nasal / Respiratory for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Dosage Delivery for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Nebulizer / Inhaler for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By DPI for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By MDI for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Nasal Spray / Inhaler for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Distribution Channel for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Prescription Outlets for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Hospital Pharmacies for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By Drugstores for the Period 2022 - 2032F
- Historical Data and Forecast of China Inhaled Corticosteroids Market Revenues & Volume By ENT Clinics for the Period 2022 - 2032F
- China Inhaled Corticosteroids Import Export Trade Statistics
- Market Opportunity Assessment By Drug Name/Form
- Market Opportunity Assessment By Indication
- Market Opportunity Assessment By Dosage Delivery
- Market Opportunity Assessment By Distribution Channel
- China Inhaled Corticosteroids Top Companies Market Share
- China Inhaled Corticosteroids Competitive Benchmarking By Technical and Operational Parameters
- China Inhaled Corticosteroids Company Profiles
- China Inhaled Corticosteroids Key Strategic Recommendations
Market Covered
This report examines the market across the segments below.
By Drug Name/Form
- Budesonide
- Fluticasone
- Beclomethasone
- Mometasone
By Indication
- Asthma / COPD
- Long-Term Inflammation
- Allergies / Wheezing
- Nasal / Respiratory
By Dosage Delivery
- Nebulizer / Inhaler
- DPI
- MDI
- Nasal Spray / Inhaler
By Distribution Channel
- Prescription Outlets
- Hospital Pharmacies
- Drugstores
- ENT Clinics
